Zai Lab Limited - American Depositary Shares (ZLAB)
26.93
+0.16 (0.60%)
Zai Lab Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for the treatment of cancer and autoimmune diseases
With a strong emphasis on research and development, Zai Lab aims to address unmet medical needs through its diverse portfolio of drug candidates, which includes both in-house programs and strategic collaborations with other biopharmaceutical companies. The company's commitment to advancing healthcare solutions is reflected in its efforts to bring novel treatments to market, thereby improving the quality of life for patients globally.
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates for solid tumors.
Key Takeaways: CEO Jason Yang has increased his CStone stake multiple times over the past 18 months to 4.79% of outstanding shares, signaling confidence in the company
